Form 8-K - Current report:
SEC Accession No. 0001029142-25-000069
Filing Date
2025-05-06
Accepted
2025-05-06 16:03:47
Documents
16
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dvax-20250506.htm   iXBRL 8-K 30232
2 EX-99.1 dvax-exx991xearningspressr.htm EX-99.1 118334
7 a1a.jpg GRAPHIC 1710
  Complete submission text file 0001029142-25-000069.txt   340597

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dvax-20250506.xsd EX-101.SCH 2705
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dvax-20250506_def.xml EX-101.DEF 16519
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dvax-20250506_lab.xml EX-101.LAB 29472
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dvax-20250506_pre.xml EX-101.PRE 17317
18 EXTRACTED XBRL INSTANCE DOCUMENT dvax-20250506_htm.xml XML 4171
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 25917141
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)